Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
Xenon Pharmaceuticals announced that Dr. Simon Pimstone, the CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:30 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals announced that Dr. Simon Pimstone, the CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:30 pm ET. Investors can access the presentation through a webcast on the company's website, with a replay available afterward. Xenon is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy, through its robust clinical-stage pipeline.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was -1.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.
A webcast will be available on the investors section of the Xenon website at http://investor.xenon-pharma.com and will be available for replay following the event.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.